Attune is a groundbreaking mobile app developed by Blue Note Therapeutics Inc. It is the first prescription digital therapeutic designed to alleviate the symptoms of anxiety and depression in cancer patients. This innovative program delivers Cognitive Behavioral Stress Management (CBSM), a well-established behavioral intervention used in cancer patients for over two decades.

Attune provides a comprehensive approach to treatment, offering cognitive behavioral therapy, relaxation therapy, stress management techniques, and coping strategies. It serves as an adjunct to other medical treatments for adult cancer patients, offering them valuable support in managing the emotional challenges associated with their diagnosis.

In recognition of its potential impact, attune received Breakthrough Therapy Designation from the U.S. Food and Drug Administration in JuneThis designation highlights the urgent need for effective mental health support for cancer patients, especially during these trying times. It is important to note that attune is only available by prescription, emphasizing its status as a regulated and evidence-based therapeutic option.